However, Qsymia® remains a treatment option in the US for obesity, but it has yet to gain approval in Europe. In a similar vein, the oral cannabinoid receptor 1 (CB1) antagonist, rimonabant, was withdrawn in 2008 after just two years of regulatory approval in Europe for management of ...